Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Selçuk Ecza Deposu Ticaret ve Sanayi A.S. (SELEC.IS)
TRY219.00
+12.40 (+6.00%)
TR IST Healthcare Medical - Pharmaceuticals
Address
Altunizade Mah. 34662
Istanbul, TR
Istanbul, TR
CEO
Mustafa Sonay Gürgen
Website
selcukecza.com.tr
IPO
2006-04-26
ISIN TRESLEC00014
Description
Selçuk Ecza Deposu Ticaret ve Sanayi A.S. operates as a crucial intermediary within the pharmaceutical supply chain, overseeing the distribution of medicinal products from manufacturers to hospitals and pharmacies. In addition to this core function, the company manages its own dedicated pharmaceutical storage facility. Established in 1958, its principal operations are based in Istanbul, Turkey. The organization is ultimately controlled as a subsidiary of Selçuk Ecza Holding A.S.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
TRY219.00
+12.40 (+6.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
3M
Beta
0.31
Float Shares
92.59M
Free Float %
14.9%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.35% | -2.91% | +21.16% | +16.59% | +48.33% | +22.76% | +67.27% | +245.63% | +1,011.34% | +3,727.96% | +4,425.42% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
219.00
Ratings Trend (MoM)
60% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 3 | +1 |
| Hold | 2 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
3.12
Safe zone
Piotroski F-Score
5 / 9
Average
MOAT Score
3 / 10
No MOAT
Composite Rating
B
Overall Score
3 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Pharmaceuticals: +7.8%+33.7% ★ Q1'26: +38.5% (vs Q1'25)
-
EPS growth Medical - Pharmaceuticals: +20.2%-118.4% Q1'26: +72,841.2% (vs Q1'25)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%-0.5% Q1'26: +0.1% (vs Q1'25)
-
EBIT margin Medical - Pharmaceuticals: +6.8%+1.1% Q1'26: +5.8% (vs Q1'25)
-
ROIC Medical - Pharmaceuticals: +6.1%+2.5% Q1'26: +14.2% (vs Q1'25)
-
Share dilution Medical - Pharmaceuticals: +0.0%+0.0% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×7.67× Q1'26: 2.29× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 2 Rev. Ana. 1 EPS Ana. |
Dec 2028 2 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
7.48B
est: 7.30B (+2.4%)
|
8.64B
est: 8.62B (+0.3%)
|
10.69B
est: 10.62B (+0.6%)
|
13.47B
est: 13.47B (+0.0%)
|
17.81B
est: 17.81B (0.0%)
|
21.03B
est: 21.01B (+0.1%)
|
26.21B
est: 26.22B (0.0%)
|
44.71B
est: 43.03B (+3.9%)
|
97.72B
est: 87.58B (+11.6%)
|
128.62B
est: 128.83B (-0.2%)
|
172.01B
est: 172.24B (-0.1%)
|
240.98B
239.41B – 242.54B
+39.9% YoY
|
290.81B
287.20B – 294.42B
+20.7% YoY
|
334.00B
319.32B – 348.69B
+14.9% YoY
|
| EBITDA |
258.35M
est: 350.06M (-26.2%)
|
333.00M
est: 413.25M (-19.4%)
|
425.92M
est: 509.28M (-16.4%)
|
643.72M
est: 645.57M (-0.3%)
|
969.93M
est: 853.71M (+13.6%)
|
899.38M
est: 1.01B (-10.7%)
|
1.33B
est: 1.26B (+5.6%)
|
3.30B
est: 2.06B (+59.8%)
|
2.33B
est: 3.73B (-37.4%)
|
6.27B
est: 5.48B (+14.4%)
|
2.71B
est: 7.33B (-63.0%)
|
10.25B
10.18B – 10.32B
+39.9% YoY
|
12.37B
12.22B – 12.52B
+20.7% YoY
|
14.21B
13.58B – 14.83B
+14.9% YoY
|
| EBIT |
241.23M
est: 323.68M (-25.5%)
|
311.90M
est: 382.10M (-18.4%)
|
397.68M
est: 470.90M (-15.5%)
|
604.80M
est: 596.91M (+1.3%)
|
908.70M
est: 789.36M (+15.1%)
|
826.44M
est: 931.20M (-11.3%)
|
1.25B
est: 1.16B (+7.2%)
|
3.19B
est: 1.91B (+67.1%)
|
1.92B
est: 3.38B (-43.2%)
|
5.63B
est: 4.97B (+13.3%)
|
1.83B
est: 6.65B (-72.5%)
|
9.30B
9.24B – 9.36B
+39.9% YoY
|
11.22B
11.08B – 11.36B
+20.7% YoY
|
12.89B
12.32B – 13.46B
+14.9% YoY
|
| Net Income |
190.70M
est: 192.51M (-0.9%)
|
243.62M
est: 288.77M (-15.6%)
|
301.10M
est: 298.08M (+1.0%)
|
391.27M
est: 390.79M (+0.1%)
|
694.90M
est: 695.52M (-0.1%)
|
586.80M
est: 596.16M (-1.6%)
|
922.71M
est: 928.40M (-0.6%)
|
2.38B
est: 2.45B (-2.7%)
|
223.21M
|
2.06B
est: 2.14B (-3.7%)
|
-379.80M
est: 895.44M (-142.4%)
|
4.90B
4.86B – 4.94B
+447.5% YoY
|
6.00B
5.95B – 6.06B
+22.5% YoY
|
6.92B
6.87B – 6.98B
+15.3% YoY
|
| SGA |
97.98M
est: 349.38M (-72.0%)
|
111.52M
est: 412.44M (-73.0%)
|
137.49M
est: 508.29M (-72.9%)
|
174.35M
est: 644.31M (-72.9%)
|
200.21M
est: 852.04M (-76.5%)
|
892.32M
est: 1.01B (-11.2%)
|
1.10B
est: 1.25B (-12.7%)
|
2.08B
est: 2.06B (+1.0%)
|
4.66B
est: 3.67B (+26.8%)
|
7.83B
est: 5.40B (+44.9%)
|
2.21B
est: 7.22B (-69.3%)
|
10.10B
10.04B – 10.17B
+39.9% YoY
|
12.19B
12.04B – 12.35B
+20.7% YoY
|
14.01B
13.39B – 14.62B
+14.9% YoY
|
| EPS |
0.31
est: 0.31 (+0.0%)
|
0.39
est: 0.47 (-16.1%)
|
0.49
est: 0.48 (+2.1%)
|
0.63
est: 0.63 (+0.1%)
|
1.12
est: 1.12 (+0.0%)
|
0.94
est: 0.96 (-2.1%)
|
1.49
est: 1.50 (-0.3%)
|
3.83
est: 3.94 (-2.8%)
|
0.36
|
3.32
est: 3.44 (-3.5%)
|
-0.61
est: 1.44 (-142.3%)
|
7.90
7.83 – 7.96
+447.5% YoY
|
9.67
9.59 – 9.75
+22.5% YoY
|
11.15
11.06 – 11.24
+15.3% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-14 | B | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-13 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-12 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-11 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-08 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-07 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-06 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-05 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-04 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
926.91M
OE per share TTM
1.49
Owner's Yield
1.40%
Maintenance CapEx ratio
36.47%
Maint CapEx / Avg PPE
4.9%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 40 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares MSCI Turkey ETF TUR | 0.73% | 1.49M | 0.59% |
| 2 | iShares MSCI Emerging Markets Small-Cap ETF EEMS | 0.03% | 125.6K | 0.72% |
| 3 | iShares MSCI EM Small Cap UCITS ETF IEMS.L | 0.03% | 115.9K | 0.74% |
| 4 | State Street SPDR MSCI Emerging Markets Small Cap UCITS ETF EMSD.L | 0.03% | 171.5K | 0.55% |
| 5 | Avantis Responsible Emerging Markets Equity ETF AVSE | 0.01% | 27.9K | 0.33% |
| 6 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.01% | 71.4K | 0.44% |
| 7 | Avantis Emerging Markets ex-China Equity ETF AVXC | 0.01% | 38.4K | 0.33% |
| 8 | iShares MSCI EM IMI Screened UCITS ETF SEDM.L | 0.01% | 101.8K | 0.18% |
| 9 | Goldman Sachs MarketBeta Emerging Markets Equity ETF GSEE | 0.00% | 6.3K | 0.45% |
| 10 | Amundi Prime Emerging Markets UCITS ETF DR (C) PRAM.L | 0.00% | 66.7K | 0.10% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
297.2K
Shares Outstanding
621.00M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ali Akcan | Chief Financial Officer & Director | — | male |
| Ali Tuna Gurgen | Business Development Director & Director | — | male |
| Ibrahim Haluk Ögütçü | Vice Chairman of the Board & Assistant GM | — | male |
| Ilker Mahmut Kalin | IR Director | — | male |
| Mustafa Sonay Gürgen | GM & Chairman of the Board | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SELEC.IS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
